In non-small-cell lung-cancer patients treated with gemcitabine chemotherapy, CAV1 immunopositivity was shown to be an independent prognostic indicator that predicts for poor disease-free survival and overall survival of patients [59]. The gene discussed is CAV1; the disease is non-small cell lung carcinoma.